News Attivare Therapeutics Awarded $6.6 Million Grant to Advance Durable Malaria Vaccine Jan 5, 2026 Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025 May 1, 2025 Attivare Therapeutics Appoints David Sherris, Ph.D. as President, CEO, and Chairman Nov 11, 2024 Harvard’s Wyss Institute Gives Startup License to Use Newly-Developed Biomaterials Oct 15, 2024 Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies Oct 2, 2024
Attivare Therapeutics to Present Preclinical Data for ATT-01 and ATT-02 at the American Association for Cancer Research (AACR) Annual Meeting 2025 May 1, 2025
Attivare licenses Wyss Institute’s immune-modulating biomaterial technology to advance immunotherapies Oct 2, 2024
